GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Athersys Inc (FRA:4LSA) » Definitions » Float Percentage Of Total Shares Outstanding

Athersys (FRA:4LSA) Float Percentage Of Total Shares Outstanding : 98.44% (As of May. 30, 2024)


View and export this data going back to 2008. Start your Free Trial

What is Athersys Float Percentage Of Total Shares Outstanding?

Float percentage of total shares outstanding is the percentage of float shares relative to the total shares outstanding. As of today, Athersys's float shares is 26.29 Mil. Athersys's total shares outstanding is 26.71 Mil. Athersys's float percentage of total shares outstanding is 98.44%.

Insider Ownership is the percentage of shares that are owned by company insiders relative to the total shares outstanding. As of today, Athersys's Insider Ownership is 0.00%.

Institutional Ownership is the percentage of shares that are owned by institutions out of the total shares outstanding. As of today, Athersys's Institutional Ownership is 4.11%.


Athersys Float Percentage Of Total Shares Outstanding Calculation

It is the percentage of float shares out of the total shares outstanding.

Athersys's Float Percentage of Total Shares Outstanding for today is calculated as follows:

Float Percentage of Total Shares Outstanding=Float Shares/Total Shares Outstanding
=26.29/26.71
=98.44%

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Athersys (FRA:4LSA) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Athersys Inc (FRA:4LSA) » Definitions » Float Percentage Of Total Shares Outstanding
Traded in Other Exchanges
Address
3201 Carnegie Avenue, Cleveland, OH, USA, 44115-2634
Athersys Inc is a biotechnology company engaged in the field of regenerative medicine. It consists of research, clinical development, manufacturing, and manufacturing process development activities. The firm's main product is Multistem cell therapy. Its clinical development programs are focused on treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, and certain pulmonary conditions. Its revenue has been derived from corporate collaborations, license agreements, and government grants.

Athersys (FRA:4LSA) Headlines

No Headlines